July 03, 2018
Exclusive panel discussions address burning questions in bioanalysis
Bioanalysis Zone presents a rare opportunity to see experts from across the pharmaceutical and CRO industries sharing perspectives on recent issues in the field of bioanalysis.
Bioanalysis Zone is delighted to offer its members unique access to two panel discussions. The panel discussions focus on two current issues facing the bioanalytical field: new technology integration in bioanalytical workflows and the sharing of scientific data.
The series focusing on new technologies features conversation between Scott Summerfield (GSK), Roger Hayes (MPI Research), Meina Liang (MedImmune), Lina Luo (Pfizer), Ian Moore (Sciex), Afshin Safavi (BioAgilytix) and Dominic Warrino (KCAS). The panelists discuss where the demand for new technologies is coming from, key barriers and the different opportunities for new technologies.
Chaired by Amanda Wilson (AstraZeneca), the panel discussion on the sharing of scientific data focuses on the best practices with data sharing in the public domain, how to write a manuscript and key advice for a young scientist. The panel comprises leading CRO and pharmaceutical leaders: Melanie Anderson (Merck), Lawrence Goodwin (KCAS), Patrick Liu (Teva pharmaceuticals), Shane Needham (Alturas Analytics) and Jason Wrigley (Merck KGaA).
Naamah Maundrell, Senior Editor of Bioanalysis Zone, commented: “We are delighted to be able to present two panel discussions to the community in what is a rare opportunity for experts from both sides of the industry to have open conversations about current issues. Our hope is that through having these discussions, together we can learn and progress the field of bioanalysis.”
Bioanalysis Zone would also like to take this opportunity to thank the speakers, as well as the sponsors of this series: BioAgilytix, KCAS, MPI Research, A Charles River Company and Sciex.
The two panel discussions can be viewed on Bioanalysis Zone:
For any enquiries email Naamah Maundrell, Senior Editor of Bioanalysis Zone, at email@example.com
About Bioanalysis Zone
Since launching in 2011, Bioanalysis Zone has attracted over 10,000 active members from the global bioanalytical community, representing the pharmaceutical, biotech and CRO industries, along with academia and healthcare. Each month, thousands of members visit the site to read industry news, peer-reviewed research, exclusive interviews, webinars and commentaries. Join the Bioanalysis Zone Twitter and LinkedIn group for updates.
About Future Science Group
Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological and scientific research. FSG’s portfolio includes two imprints, Future Science and Future Medicine. In addition to this core publishing business, FSG develops specialist eCommunities. Key titles and sites include Bioanalysis Zone, Epigenomics, Nanomedicine and the award-winning Regenerative Medicine.
The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards.